$BJDX News

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics Announces $8.5M Private Placement Of 3,655,917 Shares, With Series G And H Warrants At A Combined Price Of $2.325; Potential Additional Gross Proceeds To The Company From The Series G Warrants And The Short-Term Series H Warrants, If Fully Exercised On A Cash Basis, Will Be ~$15.1M

Why Is Bluejay Diagnostics Stock Soaring Tuesday?

Bluejay Diagnostics Announces Strategic Partnership With Argonaut Manufacturing Services To Support Advancement Of Bluejay's Symphony Platform

Bluejay Diagnostics Q1 EPS $(1.95) Up From $(13.48) YoY

Bluejay Diagnostics Completes 624 Of 750 Patient Enrollments In SYMON-II Pivotal Trial For Symphony IL-6 Sepsis Test, Expects Full Enrollment In 2 To 3 Months

Bluejay Diagnostics Completes 624 Of 750 Patient Enrollments In SYMON-II Pivotal Trial For Symphony IL-6 Sepsis Test, Expects Full Enrollment In 2 To 3 Months

Bluejay Diagnostics Provides 2026 Outlook, Says SYMON II Study And Manufacturing Scale-Up Remain On Track, Expects To Need At Least $20M In Additional Capital Through 2027

Bluejay Diagnostics Says All October 2025 Private Placement Prefunded Warrants Exercised With About 972,000 Shares Outstanding And 1.5M Cash Warrants At $7.00-Plus

Bluejay Diagnostics Enrolls 545 Patients In SYMON II Study And Reports Manufacturing Readiness Progress Including Antibody Supply For Over 10M Test Cartridges Into 2026

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Bluejay Diagnostics Announces 1-For-4 Reverse Stock Split, Effective Jan. 29

Bluejay Diagnostics Completes Commercial-Scale Production Of Polyclonal And Monoclonal Antibodies Targeting Interleukin-6, Biomarker Relevant To Inflammatory And Critical-Care Applications

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

Bluejay Diagnostics Pushes Forward with 20-Minute Sepsis Test, Reports $3M in Cash, But Needs $20M to Reach FDA Goal

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics Shares Resume Trade

Bluejay Diagnostics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 86.10%